Key result
Structural conservation of viral proteins such as proteases, helicases, methyltransferases, and polymerases provides promising pharmacological targets for novel antiviral drugs against ssRNA viruses.
Why the study?
Viral threats such as COVID-19 highlight an emerging need to identify promising pharmacological targets in viruses.
Understanding the structural conservation of key viral enzymes provides a foundation for utilizing artificial intelligence and rational drug design to develop targeted antiviral therapies.
May inform AI-driven antiviral design; leaves open clinical validation in prospective trials.
In the era of big data and artificial intelligence, a lot of new discoveries have influenced the fields of antiviral drug design and pharmacophore identification. Viruses have always been a threat to society in terms of public health and economic stability. Viruses not only affect humans but also livestock and agriculture with a direct impact on food safety, economy and environmental imprint. Most recently, with the pandemic of COVID-19, it was made clear that a single virus can have a devastating impact on global well-being and economy. In this direction, there is an emerging need for the identification of promising pharmacological targets in viruses. Herein, an effort has been made to discuss the current knowledge, state-of-the-art applications and future implications for the main pharmacological targets of single-stranded RNA viruses.
No takes yet. Share an insight, caveat, or question.
Dimitriοs Vlachakis (2021) conducted a review in ssRNA viral infections. Antiviral drug design was evaluated. Structural conservation of viral proteins such as proteases, helicases, methyltransferases, and polymerases provides promising pharmacological targets for novel antiviral drugs against ssRNA viruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: